Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Treatment options for C3 glomerulopathy.

Nester CM, Smith RJ.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):231-7. doi: 10.1097/MNH.0b013e32835da24c. Review.

2.

Eculizumab and recurrent C3 glomerulonephritis.

Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.

Pediatr Nephrol. 2013 Oct;28(10):1975-81. doi: 10.1007/s00467-013-2503-y.

3.

Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.

Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC.

Pediatr Nephrol. 2016 Apr;31(4):683-7. doi: 10.1007/s00467-015-3306-0.

PMID:
26759144
4.

Defining the complement biomarker profile of C3 glomerulopathy.

Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1876-82. doi: 10.2215/CJN.01820214.

5.

Eculizumab for treatment of rapidly progressive C3 glomerulopathy.

Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F.

Am J Kidney Dis. 2015 Mar;65(3):484-9. doi: 10.1053/j.ajkd.2014.09.025.

PMID:
25530108
6.

Treatment of C3 glomerulopathy with complement blockers.

Vivarelli M, Emma F.

Semin Thromb Hemost. 2014 Jun;40(4):472-7. doi: 10.1055/s-0034-1375299. Review.

PMID:
24799307
7.

Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.

Mol Immunol. 2016 Mar;71:131-42. doi: 10.1016/j.molimm.2016.01.010.

PMID:
26895476
8.

C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.

Xiao X, Pickering MC, Smith RJ.

Semin Thromb Hemost. 2014 Jun;40(4):465-71. doi: 10.1055/s-0034-1376334. Review.

PMID:
24799308
9.

C3 glomerulopathies. A new perspective on glomerular diseases.

Rabasco-Ruiz C, Huerta-Arroyo A, Caro-Espada J, Gutiérrez-Martínez E, Praga-Terente M.

Nefrologia. 2013;33(2):164-70. doi: 10.3265/Nefrologia.pre2012.Nov.11802. Review. English, Spanish.

10.

[C3 glomerulopathy].

Chauvet S, Servais A, Frémeaux-Bacchi V.

Nephrol Ther. 2014 Apr;10(2):78-85. doi: 10.1016/j.nephro.2013.09.007. Review. French.

PMID:
24508002
11.

Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.

Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ.

Immunobiology. 2015 Aug;220(8):993-8. doi: 10.1016/j.imbio.2015.04.001.

12.

C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT.

Clin J Am Soc Nephrol. 2014 Jan;9(1):46-53. doi: 10.2215/CJN.04700513.

13.

Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.

Okuda Y, Ishikura K, Hamada R, Harada R, Sakai T, Hamasaki Y, Hataya H, Fukuzawa R, Ogata K, Honda M.

Nephrology (Carlton). 2015 Apr;20(4):286-92. doi: 10.1111/nep.12382.

PMID:
25524631
14.

Eculizumab in the treatment of membranoproliferative glomerulonephritis.

Bomback AS.

Nephron Clin Pract. 2014;128(3-4):270-6. doi: 10.1159/000368592. Review.

15.

Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.

Hawfield A, Iskandar SS, Smith RJ.

Am J Kidney Dis. 2013 May;61(5):828-31. doi: 10.1053/j.ajkd.2012.11.045. Review.

PMID:
23391537
16.

Complement factor H-related hybrid protein deregulates complement in dense deposit disease.

Chen Q, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF.

J Clin Invest. 2014 Jan;124(1):145-55. doi: 10.1172/JCI71866.

17.

Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Rousset-Rouvière C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M.

Pediatr Nephrol. 2014 Jun;29(6):1107-11. doi: 10.1007/s00467-013-2711-5.

PMID:
24408225
18.

Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.

Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63.

19.

Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Häffner K, Michelfelder S, Pohl M.

Pediatr Nephrol. 2015 Nov;30(11):1951-9. doi: 10.1007/s00467-015-3111-9.

PMID:
25986912
20.

Complement and glomerular disease: new insights.

Pickering M, Cook HT.

Curr Opin Nephrol Hypertens. 2011 May;20(3):271-7. doi: 10.1097/MNH.0b013e328345848b. Review.

PMID:
21422921
Items per page

Supplemental Content

Support Center